Sex Differences in Tolerability to Anti‐Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non‐Small Cell Lung Cancer: Are We All Equal?

BACKGROUND. Immune‐related adverse events (irAEs) have emerged as a serious clinical issue in the use of immune checkpoint inhibitors (ICIs). Risk factors for irAEs remain controversial. Therefore, we studied sex differences in irAEs in patients treated with anti‐programmed cell death protein 1 (PD‐...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Duma, Narjust, Abdel‐Ghani, Azzouqa, Yadav, Siddhartha, Hoversten, Katherine P., Reed, Clay T., Sitek, Andrea N., Enninga, Elizabeth Ann L., Paludo, Jonas, Aguilera, Jesus Vera, Leventakos, Konstantinos, Lou, Yanyan, Kottschade, Lisa A., Dong, Haidong, Mansfield, Aaron S., Manochakian, Rami, Adjei, Alex A., Dronca, Roxana S.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2019
Témata:
Immuno‐Oncology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853107/
https://ncbi.nlm.nih.gov/pubmed/31036771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0094
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky